摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R)-3-(2-Hydroxy-2-thien-2-ylheptanoyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate | 440674-36-2

中文名称
——
中文别名
——
英文名称
(3R)-3-(2-Hydroxy-2-thien-2-ylheptanoyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate
英文别名
[(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-thiophen-2-ylheptanoate;2,2,2-trifluoroacetate
(3R)-3-(2-Hydroxy-2-thien-2-ylheptanoyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate化学式
CAS
440674-36-2
化学式
C2F3O2*C27H38NO4S
mdl
——
分子量
585.685
InChiKey
AWBZUDUZPSVGFK-ZTYMJOMLSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.44
  • 重原子数:
    40
  • 可旋转键数:
    13
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    124
  • 氢给体数:
    1
  • 氢受体数:
    10

文献信息

  • Novel quinuclidine derivatives and medicinal compositions containing the same
    申请人:——
    公开号:US20040072863A1
    公开(公告)日:2004-04-15
    A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group, —OR 7 , —SR 7 , —NR 7 R 8 , —NHCOR 7 , —CONR 7 R 8 , —CN, —NO 2 , —COOR 7 or CF 3 group, or a strait or branched, substituted or unsubstituted lower alkyl group, wherein R 7 and R 8 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic or alicyclic ring or a heterocyclic group. n is an integer from 0 to 4; A represents a group selected from —CH 2 —, —CH═CR 9 —, —CR 9 ═CH—, —CR 9 R 10 —, —CO—, —O—, —S—, —S(O)—, —S(O) 2 — and NR 9 , wherein R 9 and R 10 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; m is an integer from 0 to 8, provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azonia bicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; R 4 represents a group of structure: (Formulae II) wherein R 11 represents a hydrogen or halogen atom, a hydroxy group, an alkoxy group, a nitro group, a cyano group, —CO 2 R 12 or —NR 12 R 13 , wherein R 12 and R 13 are identical or different and are selected from hydrogen and straight or branched lower alkyl groups, or a straight or branched, substituted or unsubstituted lower alkyl group; R 5 represents an alkyl group of 1 to 7 carbon atoms, an alkenyl group containing 2 to 7 carbon atoms, or a group of formula (III) wherein q=1 or 2 and R 11 iss a defined above; R 6 represents a hydrogen atom, a hydroxy group, a methyl group or a —CH 2 OH group; and X − represents a pharmaceutically acceptable anion of a mono or polyvalent acid. 1
    式(I)的化合物,其中B是苯环、含有一个或多个杂原子的5至10元杂芳香族基团,或基、5,6,7,8-四氢基、苯并[1,3]二氧杂环戊基或联苯基团;R1、R2和R3各自独立地表示氢或卤素原子,或羟基、苯基、—OR7、—SR7、—NR7R8、—NHCOR7、—CONR7R8、—CN、—NO2、—COOR7或CF3基团,或直链或支链、取代或未取代的低级烷基基团,其中R7和R8各自独立地表示氢原子、直链或支链的低级烷基基团,或一起形成脂环族环;或者R1和R2一起形成芳香族或脂环族环或杂环基团。n是0至4的整数;A表示选自—CH2—、—CH═CR9—、—CR9═CH—、—CR9R10—、—CO—、—O—、—S—、—S(O)—、—S(O)2—和NR9的基团,其中R9和R10各自独立地表示氢原子、直链或支链的低级烷基基团,或一起形成脂环族环;m是0至8的整数,条件是当m=0时,A不是— —;p是1至2的整数,并且氮杂双环环上的取代可以在2、3或4位,包括所有可能的不对称碳构型;R4表示具有结构:(式II)的基团,其中R11表示氢或卤素原子、羟基、烷氧基、硝基、基、—CO2R12或—NR12R13,其中R12和R13相同或不同,并选自氢和直链或支链的低级烷基基团,或直链或支链、取代或未取代的低级烷基基团;R5表示1至7个碳原子的烷基基团、含有2至7个碳原子的烯基基团,或具有式(III)的基团,其中q=1或2,且R11如上定义;R6表示氢原子、羟基、甲基或— OH基团;X-表示药物上可接受的单或多元酸的阴离子。
  • NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
    申请人:PRAT QUINONES Maria
    公开号:US20100234332A1
    公开(公告)日:2010-09-16
    A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl. 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group, —OR 7 , —SR 7 , —NR 7 R 8 , —NHCOR 7 , —CONR 7 R 8 , —CN, —NO 2 , —COOR 7 or CF 3 group, or a strait or branched, substituted or unsubstituted lower alkyl group, wherein R 7 and R 8 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic or alicyclic ring or a heterocyclic group. n is an integer from 0 to 4; A represents a group selected from —CH 2 —, —CH═CR 9 —, —CR 9 ═CH—, —CR 9 R 10 —, —CO—, —O—, —S—, —S(O)—, —S(O) 2 — and NR 9 , wherein R 9 and R 10 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; m is an integer from 0 to 8, provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azonia bicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; R 4 represents a group of structure: (Formulae II) wherein R 11 represents a hydrogen or halogen atom, a hydroxy group, an alkoxy group, a nitro group, a cyano group, —CO 2 R 12 or —NR 12 R 13 , wherein R 12 and R 13 are identical or different and are selected from hydrogen and straight or branched lower alkyl groups, or a straight or branched, substituted or unsubstituted lower alkyl group; R 5 represents an alkyl group of 1 to 7 carbon atoms, an alkenyl group containing 2 to 7 carbon atoms, or a group of formula (III) wherein q=1 or 2 and R 11 is a defined above; R 6 represents a hydrogen atom, a hydroxy group, a methyl group or a —CH 2 OH group; and X − represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
    化合物的公式(I),其中B是苯环,含有一个或多个杂原子的5到10个成员的杂芳族基团,或基,5,6,7,8-四氢基,苯并[1,3]二噁英基或联苯基;R1,R2和R3各自代表氢或卤素原子,或羟基,苯基,-OR7,-SR7,-NR7R8,-NHCOR7,-CONR7R8,-CN,-NO2,-COOR7或CF3基团,或直链或支链,取代或未取代的较低烷基基团,其中R7和R8各自代表氢原子,直链或支链较低烷基基团,或一起形成脂环;或R1和R2一起形成芳香族或脂环或杂环基团。n为0到4的整数;A表示从-CH2,-CH═CR9,-CR9═CH-,-CR9R10,-CO-,-O-,-S-,-S(O)-,-S(O)2-和NR9中选择的基团,其中R9和R10各自代表氢原子,直链或支链较低烷基基团,或一起形成脂环;m为0到8的整数,前提是当m=0时,A不是- -;p为1到2的整数,并且氮杂双环环中的取代基可以在2、3或4位,包括不对称碳的所有可能构型;R4表示结构的基团:(公式II),其中R11表示氢或卤素原子,羟基,烷氧基,硝基,基,-CO2R12或-NR12R13,其中R12和R13相同或不同,并选择自氢和直链或支链较低烷基基团,或直链或支链,取代或未取代的较低烷基基团;R5表示1到7个碳原子的烷基基团,含有2到7个碳原子的烯基基团,或公式(III)中的基团,其中q=1或2且R11如上所述;R6表示氢原子,羟基,甲基或- OH基团;X-表示单价或多价酸的药用可接受的阴离子。
  • US7122558B2
    申请人:——
    公开号:US7122558B2
    公开(公告)日:2006-10-17
  • US7879874B2
    申请人:——
    公开号:US7879874B2
    公开(公告)日:2011-02-01
  • US7893087B2
    申请人:——
    公开号:US7893087B2
    公开(公告)日:2011-02-22
查看更多

同类化合物

麦可弗汀A 罗哌卡因杂质 六氢-2-甲基-2H-吡啶并[1,2-a]吡嗪-1,6-二酮 八氢吡啶并〔1,2-A〕吡嗪-6-酮 八氢吡啶并[1,2-a]吡嗪 八氢-吡啶并[1,2-A]吡嗪-4-酮盐酸盐 八氢-6H-吡啶并[1,2-a]吡嗪-6-酮盐酸盐 八氢-3-甲基-2H-吡啶并[1,2-a]吡嗪 八氢-2H-吡啶并[1,2-a]吡嗪二盐酸盐 八氢-2H-吡啶并[1,2-a]吡嗪-6-甲醇 7-甲氧基辛a氢-2H-吡啶并[1,2-a]吡嗪-2-胺 7-乙基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 6-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 4H-吡唑[1,2-A]吡嗪-4-八氢酮 3-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 2-苄基八氢-1H-吡啶并[1,2-a]吡嗪 2-硝基八氢-2H-吡啶并[1,2-a]吡嗪 2-乙基六氢-2H-吡啶并[1,2-a]吡嗪-1(6H)-酮 2-(9-甲基-3,9-二氮杂双环[3.3.1]壬-3-基)乙胺 2-(4-甲硫基唑-5-基)乙基丁酸酯 2,3,4,6,7,8,9,9alpha-八氢-1H-吡啶并[1,2-a]吡嗪-3-基甲醇 1,1'-联苯基,2-乙基-5-甲氧基- (R)-八氢吡啶并[1,2-A〕吡嗪二盐酸盐 (9aS)-八氢-4H-吡啶并[1,2-a]吡嗪-4-酮 (9aR)-八氢-2H-吡啶并[1,2-a]吡嗪 (9SS)-八氢-2-吡啶-吡嗪盐酸盐[1,2-A] (7r,9as)-八氢-2H-吡啶并[1,2-a]吡嗪-7-甲醇 (3S,6S)-3-苄基-1,4-二氮杂双环[4.4.0]癸烷-2,5-二酮 ((7S,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-7-基)甲醇 ((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇 cyclo-(D-Leu-D-Pip) (3S,9aR)-hexahydro-3-methyl-6H-pyrido[1,2-a]pyrazine-1,4-dione (9aS)-2-benzyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine 3-[3-(1,3,4,6,7,8,9,9a-Octahydropyrido[1,2-a]pyrazine-2-carbonyl)-2-methoxyanilino]-4-(2-chloro-3-fluoroanilino)cyclobut-3-ene-1,2-dione (7R,9aS)-trans-7-(3-morpholin-4-ylmethylphenoxymethyl)-octahydro-pyrido[1,2-a]pyrazine-2-carboxylic acid tert-butyl ester 3-[3-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl)-2-methoxyanilino]-4-[[(1R)-1-phenylpropyl]amino]cyclobut-3-ene-1,2-dione 3-Chinolizidin-1-yl-2-methylindol 2-propyl-octahydro-pyrido[1,2-c][1,3,6]oxadiazocine (8R,9aS)-2-benzyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl cyclohexylcarbamate 2-(5-Amino-2-methoxy-phenyl)-hexahydro-pyrido[1,2-a]pyrazin-3-one 14α-hydroxy-15α-methyl-16β-methylsulfinyl-17-oxomarcfortine A (1S,7S,10S)-12-Acetyl-9-thia-3,12-diaza-tricyclo[8.2.1.03,7]tridecan-2-one (4-Aminophenyl)-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)methanone 3-Benzylaminomethyl-chinolizidin rac-(4aR,8aR)-1-(piperidin-3-yl)-decahydroquinoline (1S,7R,10S)-12-Acetyl-9-thia-3,12-diaza-tricyclo[8.2.1.03,7]tridecan-2-one N-((1R,2S,5R)-2-((S)-3-amino-2-oxopyrrolidin-1-yl)-5-(isopropylamino)cyclohexyl)acetamide 2-tert-butylperhydroimidazolo<3,4-a>pyridine 1,3,4,6,7,8,9,9a-Octahydropyrido[1,2-a]pyrazin-2-yl-(2-chloro-5-phenylthiophen-3-yl)methanone 3-[2-oxo-2-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,9-diazaspiro[2.6]nonan-9-yl]ethyl]thiazolidine-2,4-dione